Literature DB >> 34347213

To inhibit or to boost the ATP/P2RX7 pathway to fight cancer-that is the question.

Serena Janho Dit Hreich1,2,3, Jonathan Benzaquen1,2,3, Paul Hofman1,2,3,4,5, Valérie Vouret-Craviari6,7,8.   

Abstract

Despite new biological insights and recent therapeutic advances, many tumors remain at baseline during treatments. Therefore, there is an urgent need to find new therapeutic strategies to improve the care of patients with solid tumors. P2RX7 receptor (P2XR7), an ATP-gated ion channel characterized by its ability to form large pore within the cell membrane, is described by most of the investigators as a "chef d'orchestre" of the antitumor immune response. The purpose of this review is to detail the recent information concerning different cellular mechanisms linking P2RX7 to hallmarks of cancer and to discuss different progresses in elucidating how activation of the ATP/P2RX7/NLRP3/IL-18 pathway is a very promising approach to fight cancer progression by increasing antitumor immune responses.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Antitumor immunity; Ectonucleases; Immunotherapies; P2X7; Purinergic signaling; Tumors

Mesh：

Substances：

Year:  2021        PMID： 34347213      PMCID： PMC8677881          DOI： 10.1007/s11302-021-09811-9

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN： 1573-9538            Impact factor:   3.765


  137 in total

1.  Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors.

Authors:  Marco Idzko; Stefan Dichmann; Davide Ferrari; Francesco Di Virgilio; Andrea la Sala; Giampiero Girolomoni; Elisabeth Panther; Johannes Norgauer
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

Review 2.  Tumors as organs: complex tissues that interface with the entire organism.

Authors:  Mikala Egeblad; Elizabeth S Nakasone; Zena Werb
Journal:  Dev Cell       Date:  2010-06-15       Impact factor: 12.270

Review 3.  The Elusive P2X7 Macropore.

Authors:  Francesco Di Virgilio; Günther Schmalzing; Fritz Markwardt
Journal:  Trends Cell Biol       Date:  2018-02-10       Impact factor: 20.808

4.  Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerves in the gut.

Authors:  G Burnstock; G Campbell; D Satchell; A Smythe
Journal:  Br J Pharmacol       Date:  1970-12       Impact factor: 8.739

5.  Extracellular ATP4- promotes cation fluxes in the J774 mouse macrophage cell line.

Authors:  T H Steinberg; S C Silverstein
Journal:  J Biol Chem       Date:  1987-03-05       Impact factor: 5.157

6.  Accelerated tumor progression in mice lacking the ATP receptor P2X7.

Authors:  Elena Adinolfi; Marina Capece; Alessia Franceschini; Simonetta Falzoni; Anna L Giuliani; Alessandra Rotondo; Alba C Sarti; Massimo Bonora; Susanne Syberg; Domenica Corigliano; Paolo Pinton; Niklas R Jorgensen; Luigi Abelli; Laura Emionite; Lizzia Raffaghello; Vito Pistoia; Francesco Di Virgilio
Journal:  Cancer Res       Date:  2014-12-26       Impact factor: 12.701

7.  THE METABOLISM OF TUMORS IN THE BODY.

Authors:  O Warburg; F Wind; E Negelein
Journal:  J Gen Physiol       Date:  1927-03-07       Impact factor: 4.086

8.  Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma.

Authors:  Anna Lisa Giuliani; Davide Colognesi; Tiziana Ricco; Carlotta Roncato; Marina Capece; Francesca Amoroso; Qi Guang Wang; Elena De Marchi; Allison Gartland; Francesco Di Virgilio; Elena Adinolfi
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

9.  Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.

Authors:  Anna Solini; Vittorio Simeon; Lisa Derosa; Paola Orlandi; Chiara Rossi; Andrea Fontana; Luca Galli; Teresa Di Desidero; Anna Fioravanti; Sara Lucchesi; Luigi Coltelli; Laura Ginocchi; Giacomo Allegrini; Romano Danesi; Alfredo Falcone; Guido Bocci
Journal:  Oncotarget       Date:  2015-10-06

10.  P2RX7B is a new theranostic marker for lung adenocarcinoma patients.

Authors:  Jonathan Benzaquen; Serena Janho Dit Hreich; Simon Heeke; Thierry Juhel; Salomé Lalvee; Serge Bauwens; Simona Saccani; Philippe Lenormand; Véronique Hofman; Mathilde Butori; Sylvie Leroy; Jean-Philippe Berthet; Charles-Hugo Marquette; Paul Hofman; Valérie Vouret-Craviari
Journal:  Theranostics       Date:  2020-08-29       Impact factor: 11.556
View more
  4 in total

1.  Potentiating Cancer Immune Therapy via Nanomaterials and Purinergic Signaling.

Authors:  Davide Ferrari; Stefania Gessi; Stefania Merighi; Manuela Nigro; Alessia Travagli; Jorge S Burns
Journal:  Front Cell Dev Biol       Date:  2022-05-04

Review 2.  The Purinergic Landscape of Non-Small Cell Lung Cancer.

Authors:  Serena Janho Dit Hreich; Jonathan Benzaquen; Paul Hofman; Valérie Vouret-Craviari
Journal:  Cancers (Basel)       Date:  2022-04-11       Impact factor: 6.575

Review 3.  Ligand-Gated Ion Channels as Targets for Treatment and Management of Cancers.

Authors:  Rohan Rao; Sanjit Shah; Debanjan Bhattacharya; Donatien Kamdem Toukam; Román Cáceres; Daniel A Pomeranz Krummel; Soma Sengupta
Journal:  Front Physiol       Date:  2022-03-08       Impact factor: 4.566

4.  A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients.

Authors:  Julie Le Naour; Zsofia Sztupinszki; Vincent Carbonnier; Odile Casiraghi; Virginie Marty; Lorenzo Galluzzi; Zoltan Szallasi; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2022-04-17       Impact factor: 7.723
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.